Prospective Evaluation of Infants With Spinal Muscular Atrophy:
study id #: NCT02831296
condition: Spinal Muscular Atrophy
status: Recruiting
purpose:SPOT SMA is a prospective NIH-supported clinical study targeting pre-symptomatic or recently diagnosed infants and children with Spinal Muscular Atrophy (SMA) types 1, 2, or 3 and their healthy control siblings less than 36 months of age at the time of study enrollment. The main objective of the study is to prospectively collect longitudinal clinical outcomes and provide counseling and education to parents of newly diagnosed children. The study will assess the impact of current standard of care management paradigms and interventions on health outcomes in newly diagnosed SMA infants and children with type 1, 2 or 3 and age appropriate controls. There is no investigational drug and no specific intervention in this study. Rather, the investigators will document outcomes related to current therapies provided to participating subjects, and will educate participants about possible clinical trial opportunities.
results: https://clinicaltrials.gov/ct2/show/results/NCT02831296
last updated: February 04, 2022
-
Boston Children’s Hospital – Spinal Muscular Atrophy ProgramThe Spinal Muscular Atrophy Program at B...
-
Nonrespiratory Complications of Nusinersen-Treated Spinal Muscular Atrophy Type 1 PatientsBackground: Emergence of new treatments ...
-
DNA From Saliva Has Potential for Detecting SMAA noninvasive method using dried saliva ...
-
Gene Therapy for SMA Type 1: Evelyn’s Storyhttps://www.youtube.com/watch?v=yRrqbvUv...
-
Kathie Bishop, PhDKathie Bishop is a Ph.D level neuroscien...
-
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database AnalysisSpinal muscular atrophy (SMA) is a rare,...
-
Comparative All-Cause Mortality Among a Large Population of Patients With Spinal Muscular Atrophy Versus Matched Con...Introduction: There is little informatio...